XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2020   41,596,253      
Beginning balance at Dec. 31, 2020 $ (1,151,733) $ 4,159 $ 70,366,293 $ (91,388) $ (71,430,797)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 365,911   365,911    
Issuance of common stock, net of issuance costs (in shares)   5,664,069      
Issuance of common stock, net of issuance costs 11,324,140 $ 567 11,323,573    
Issuance of common stock from the exercise of warrants (in shares)   52,500      
Issuance of common stock from the exercise of warrants 50,400 $ 5 50,395    
Net loss (7,323,644)       (7,323,644)
Foreign currency translation adjustments (6,841)     (6,841)  
Ending balance (in shares) at Mar. 31, 2021   47,312,822      
Ending balance at Mar. 31, 2021 3,258,233 $ 4,731 82,106,172 (98,229) (78,754,441)
Beginning balance (in shares) at Dec. 31, 2021   83,944,119      
Beginning balance at Dec. 31, 2021 38,754,321 $ 8,394 149,027,802 (154,973) (110,126,902)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 532,409   532,409    
Net loss (8,398,670)       (8,398,670)
Foreign currency translation adjustments (9,150)     (9,150)  
Ending balance (in shares) at Mar. 31, 2022   83,944,119      
Ending balance at Mar. 31, 2022 $ 30,878,910 $ 8,394 $ 149,560,211 $ (164,123) $ (118,525,572)